The promyelocytic leukemia nuclear body: Sites of activity?

Biochemistry and Cell Biology

Volumn 80, Issue 3, 2002, Pages 301-310

  Eskiw, Christopher H ^a   Bazett Jones, David P ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Nuclear bodies; Nucleus; Promyelocytic leukemia; Transcription

Indexed keywords

CELLS; DISEASES; PATIENT TREATMENT; PROTEINS;

CELLULAR STRESSES;

BIOCHEMISTRY;

HYBRID PROTEIN; NUCLEAR PROTEIN; RETINOIC ACID RECEPTOR ALPHA; SUMO 1 PROTEIN; PML PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

CANCER CHEMOTHERAPY; CELL CYCLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL NUCLEUS; CELL NUCLEUS INCLUSION BODY; CONFERENCE PAPER; EUKARYOTIC CELL; GENETIC TRANSCRIPTION; HEAT SHOCK; HUMAN; LEUKEMIA CELL; MOLECULAR DYNAMICS; MOLECULAR MODEL; PHENOTYPE; PROMYELOCYTIC LEUKEMIA; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REGULATORY MECHANISM; STRESS; VIRUS INFECTION; CELL INCLUSION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; ULTRASTRUCTURE;

CELL CYCLE; CELL NUCLEUS; HUMAN; INCLUSION BODIES; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SUPPORT, NON-U.S. GOV'T; TRANSCRIPTION FACTORS; HUMANS; NUCLEAR PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EUKARYOTA;

EID: 0035986065     PISSN: 08298211     EISSN: None     Source Type: Journal    
DOI: 10.1139/o02-079     Document Type: Conference Paper

References (125)

1. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies
2. Disruption of PML associated nuclear bodies by IE1 correlates with efficient early stages of viral gene expression and DNA replication in human cytomegalovirus
3. Disruption of PML subnuclear domain by the acidic IE1 protein of human cytomegalovirus is mediated through interactions with PML and may modulate a RING finger-dependent cryptic transactivator function of PML
4. Expression pattern of the RARa-PML fusion gene in acute promyelocytic leukemia
5. Fluorescence in situ hybridization: A highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias
6. Histone deacetylase inhibitors induce caspase-dependent apoptosis and down regulation of daxx in acute promyelocytic leukaemia with t(15;17)
7. Electron spectroscopic imaging of chromatin
8. Hepatitis delta virus replication generates complexes of large hepatitis delta antigen and antigenomic RNA that affiliate with and alter nuclear domain 10
9. PIC1, a novel ubiquitin-like protein which interacts with the PML component of a multiple protein complex that is disrupted in acute promyelocytic leukemia
10. Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA
11. The transcriptional coactivator CBP is a dynamic component of the promyelocytic leukemia nuclear body
12. The solution structure of the RING finger domain from the acute promyelocytic leukemia proto-oncogene PML
13. In vitro and in vivo characterization of the B1 and B2 zinc-binding domains from the acute promyelocytic leukemia proto-oncogene PML
14. Two RING finger proteins, the oncogenic PML and the arenavirus Z protein, colocalize with the nuclear fraction of the ribosomal P protein
15. An arenavirus RING (zinc-binding) protein binds the oncoprotein PML and the arenavirus Z protein, co-localize with the nuclear fraction of the ribosomal P proteins
16. Nuclear bodies (NBs): A newly "rediscovered" organelle
17. Interaction of herpes simplex virus type I with ND10 and recruitment of PML to replication compartments
18. The lymphocytic choriomeningitis virus RING protein Z associates with eukaryotic initiation factor 4E and selectively represses translation in a RING-dependent manner
19. Targetting of the adenovirus E1A and E4 ORF3 proteins to nuclear matrix-associated PML bodies
20. Role of CBP/p300 in nuclear receptor signalling
21. The PML gene encodes a phosphoprotein associated with the nuclear matrix
22. Altered ligand binding and transcriptional regulation by mutations in the PML/RARa ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia
23. Acetylation of HIV-1 Tat by CBP/p300 increases transcription of integrated HIV-1 genome and enhances binding to core histones
24. Examen au microspe életronique de la tameur VX2 du lapin domestice derive du papillome de shope
25. Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF
26. Role of the promyelocytic leukemia protein PML in the interferon sensitivity of lymphocyticchoriomeningitis virus
27. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis
28. The promyelocytic (PML) nuclear compartment and transcription control
29. The PML nuclear compartment and cancer
30. Human T-cell leukemia retrovirus-Tax protein is a repressor of nuclear receptor signaling
31. The PML-retinoic acid receptor a translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1
32. Retinoic acid enhances growth of human early erythroid progenitor cells in vitro
33. Identification of PML oncogenic domains (PODs) in human megakaryocytes
34. SUMO-1 modification of the acute promyelocitic leukemia protein PML: Implications for nuclear localization
35. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein
36. Interferon-induced antiviral Mx1 GTPase is associated with components of the SUMO-1 system and promyelocytic leukemia protein nuclear bodies
37. ICP0 induces the accumulation of colocalizing conjugated ubiquitin
38. HSV-1 IE protein Vmw110 causes redistribution of PML
39. Point mutations in the herpes simplex virus type-I Vmw110 RING finger helix affect activation of gene expression, viral growth, and interaction with PML-containing nuclear structures
40. A dynamic connection between centromeres and ND10 proteins
41. Cell cycle regulation of PML modification and ND10 composition
42. Regulation of p53 in nuclear bodies by a specific PML isoform
43. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 inducescontemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies
44. The acute promyelocytic leukemia-specific PML-RARa fusion protein inhibits differentiation and promotes survival of myeloid precursor cells
45. ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle
46. The interferon (IFN)-stimulated gene Sp100 promoter contains an IFN-gamma activation site and an imperfect IFN-stimulated response element which mediate type I IFN inducibility
47. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia
48. Direct visulaization of a protein nuclear architecture
49. Induction of the pro-myelocytic leukaemia gene by type I and type II interferons
50. Covalent modification of the transactivator protein IE2-p86 of human cytomegalovirus by conjugation to the ubiquitin-homologous proteins SUMO-1 and hSMT3b
51. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2
52. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
53. The periphery of nuclear domain 10 (ND10) as site of DNA virus deposition
54. Human cytomegalovirus immediate early interaction with host nuclear structures: Definition of an immediate transcription environment
55. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1
56. PML protein isoforms and the RBCC/TRIM motif
57. Role of the heat shock response and molecular chaperones in oncogenesis and cell death
58. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML
59. Identification of three major sentrinization sites in PML
60. Human-herpesvirus-8-encoded K8 protein colocalizes with the promyelocytic leukemia protein (PML) bodies and recruits p53 to the PML bodies
61. Herpes simplex virus 1 alpha regulatory protein ICP0 interacts with and stabilizes the cell cycle regulator cyclin D3
62. Disruption of PML-associated nuclear bodies during human cytomegalovirus infection
63. The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E
64. Role of PML and PML-RARalpha in Mad-mediated transcriptional repression
65. PML-RARalpha alleviates the transcriptional repression mediated by tumor suppressor Rb
66. Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type I promoter
67. Leukemia-associated retinoic acid receptor a fusion partners, PML and PLZ, heterodiamerize and colocalize to nuclear bodies
68. The nuclear domain 10 (ND10) is disrupted by the human cytomegalovirus gene product IE1
69. Reduced mobility of the alternative splicing factor (ASF) through the nucleoplasm and steady state speckle compartment
70. Functional analysis and intracellular localization of p53 modified by SUMO-1
71. The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA
72. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs
73. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation
74. Localization of nascent RNA and CREB binding protein with PML-containing nuclear bodies
75. Analysis of the growth and transformation suppresor domains of promyelocytic leukemia gene, PML
76. Regulation of Pax3 transcriptional activity by SUMO-1-modified PML
77. The adenovirus type 5 E1b 55K and E4 Orf3 proteins associate in infected cells and affect ND10 components
78. Herpes simplex virus type 1 prereplicative sites are a heterogeneous population: Only a subset are likely to be precursors to replication compartments
79. Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells
80. The nuclear location of PML, a cellular member of the C3HC4 zinc-binding domain protein family, is rearranged during herpes simplex virus infection by the C3HC4 viral protein ICP0
81. Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0)
82. Nuclear domain 10 (ND10) associated proteins are also present in nuclear bodies and redistributed to hundreds of nuclear sites after stress
83. Review: Properties and assembly mechanisms of ND10, PML bodies and PODs
84. Deconstructing a disease: RARa, its fusion partners, and their roles in pathogenesis of acute promyelocytic leukemia
85. Histone deacetylases: A common molecular target for differentiation treatment of acute myeloid leukemias?
86. Evaluation of colocalization interactions between the IE110, IE175, and IE63 transactivator proteins of herpes simplex virus within subcellular punctate structures
87. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption
88. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus
89. Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors
90. RARs and RXRs: Evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodiamerization in vivo
91. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot
92. Evidence for a separate ND10-binding and homo-oligerization domains of Sp100
93. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein
94. Characterization of an E1A-CBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300
95. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties
96. Alphaherpesvirus proteins related to herpes simplex virus type I ICP0 affect cellular structure and proteins
97. PML interaction with p53 and its role in apoptosis and replicative senescence
98. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras
99. PML induces a novel caspase-independent death process
100. SUMO-1 modification of bovine papillomavirus E1 protein is required for intranuclear accumulation
101. Role and fate of PML nuclear bodies in response to interferon and viral infections
102. PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator
103. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RARa) and PLZF-RARa fusion proteins on retinoic acid signalling
104. PML bodies associate specifically with the MHC gene cluster in interphase nuclei
105. Macromolecular domains within the cell nucleus
106. RNA processing. Cycling splicing factors
107. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC/SUMO-1
108. Human papillomavirus DNA replication compartments in a transient DNA replication system
109. The Epstein-Barr virus encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies
110. Human herpesvirus-8-encoded LNA-1 accumulates in heterochromatin-associated nuclear bodies
111. Adenovirus early E4 genes in viral oncogenesis
112. The promyelocytic leukemia protein PML interacts with the proline-rich homeodomain PRH: A RING may link hematopoiesis and growth control
113. Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: Interference with early steps of viral replication
114. Interferon-b induces S phase slowing via up-regulated expression of PML in squamous carcinoma cells
115. Role of cyclin D3 in the biology of herpes simplex virus 1 ICP0
116. PML is essential for multiple apoptotic pathways
117. Retinoic acid regulates aberrant nuclear localisation of PML-RARa in acute promyelocytic leukemia
118. Disruption of PML-associated nuclear bodies mediated by the human cytomegalovirus major immediate early gene product
119. Origin-independent assembly of Kapsoi's sarcoma-associated herpesvirus DNA replication compartments in transient cotransfection assays and associated with the ORF-K8 protein and cellular PML
120. The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases
121. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression
122. Accelerated degradation of PML-retinoic acid receptor a (PML-RARa) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: Possible role of the proteosome pathway
123. The transcriptional role of PML and the nuclear body
124. Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis
125. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis